Navigation Links
Onconase in Medical News

Alfacell Announces Management Update

... rolling New Drug Application (NDA) submission for onconase in patients suffering from unresectable malignant ...eeting at the end of January 2009. About onconase (R) onconase is a first-in-class therapeutic product candidate ...

Alfacell Reports Financial Results for First Quarter of Fiscal 2009

...leted a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...etails of the planned NDA submission. About onconase (R) onconase is a first-in-class therapeutic product candidate ...

Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast

...nd other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of onconase in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com . Safe Harbor This press releas...
Onconase in Medical Technology

Alfacell's Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies

BLOOMFIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation's ONCONASE (ranpirnase) has shown potential to act as a potent payload in antibody conjugates for cancer therapy, according to the latest edition of the Handbook of Therapeutic Antibodies. In a chapter of the text th...

Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells

Poster Presented at AACR Annual Meeting BLOOMFIELD, N.J., April 16, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that in vivo and in vitro preclinical data presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting show that ONCONASE (ranpirn...

Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's Onconase

BLOOMFIELD, N.J., March 22, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today reported that in vitro studies show mild hyperthermia enhances the therapeutic effects of ONCONASE (ranpirnase), the company's lead investigational drug candidate. In a paper entitled, "Mild hyperthermia predis...

Researchers Identify Intracellular Pathway of Alfacell's Onconase

Paper Published in Journal of Cell Science Shows ONCONASE Uptake in Cells Differs from other RNases BLOOMFIELD, N.J., April 05, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that European researchers have identified the pathway that ONCONASE (ranpirnase) follows to enter cell...

Alfacell Provides Shareholder Update

...ofile, its ability to overcome MDR, I believe that onconase remains a viable candidate for second line therapy in MM. The fact that onconase was able to extend the lives of patients who had f...tudies on immune deficient mice to see what effect onconase would have on human tumors grafted onto these mice...

Alfacell Provides ONCONASE(R) NDA Submission Update

... planned submission of the final components of the onconase rolling New Drug Application (NDA) for the treatme... planned submission of the final components of the onconase rolling NDA for patients that have failed prior ch...y. Therefore, the final components of the rolling onconase NDA will not be finalized until Alfacell receives ...

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

...py. The study demonstrated that the combination of onconase and rosiglitazone synergistically decreased cell v... The study concludes the novel drug combination of onconase and rosiglitazone is a promising combination. "T... in vivo studies and demonstrates the potential of onconase for effective use in cancer treatments via multipl...

Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel

...product in our oncology portfolio. We believe that onconase will prove to be a promising new treatment option ...with an ideal partner to maximize the potential of onconase in this region. We look forward to a successful co...llaboration with Megapharm." About ONCONASE(R) onconase is a first-in-class therapeutic product candidate ...

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial

...ry Phase IIIb clinical trial of its lead compound, onconase (ranpirnase), did not meet statistical significanc...MM patients who were treated with a combination of onconase plus doxorubicin as compared to patients who were ...val time (MST) for evaluable patients who received onconase plus doxorubicin was 11.1 months as compared to 10...

Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial

...MM patients who were treated with a combination of onconase plus doxorubicin as compared to patients who were ...val time (MST) for evaluable patients who received onconase plus doxorubicin was 11.1 months as compared to 10...ntering this clinical trial. Patients who received onconase plus doxorubicin experienced a MST of 10.5 months ...

More>>

Onconase in Biological Technology

Alfacell Provides ONCONASE(R) NDA Submission Update

... planned submission of the final components of the onconase rolling New Drug Application (NDA) for the treatme...rom the confirmatory Phase IIIb clinical trial for onconase in patients suffering from UMM did not meet statis...ation effective as of January 1, 2009. About onconase (R) ...

Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells

...ct 4205 & 2008 112: Abstract 4010) report that onconase (ranpirnase) and R-Amphinase (R-Amph) show anti-tu...tment of Pathology at New York Medical College . onconase and R-Amph are amphibian endoribonucleases with un...ammed cell death) of malignant cells. Previously, onconase has been shown to affect multiple cellular pathway...

Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results

...nt in a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...ses required to complete the final sections of the onconase rolling NDA. As the company has previously reporte...nd completion of the Phase IIIb clinical trial for onconase in UMM. In fiscal 2009, we plan to complete the ND...

Paper in Cell Cycle Reports Alfacell's ONCONASE(R) Targets siRNA

...n Cell Cycle (2008; Vol. 7, Issue 20) reports that onconase (ranpirnase) targets small interfering RNA (siRNA)...he expression was restored in the cells exposed to onconase for 48 or 72 hours. The data thus provide evidence...his data provide further evidence of the impact of onconase on the RNAi mechanism," said Kuslima Shogen, Alfac...

Alfacell Hires Advisors to Advance Strategic Alternatives

...oved a specific transaction. About ONCONASE(R) onconase is a first-in-class therapeutic product candidate ... A natural protein isolated from the leopard frog, onconase has been shown in the laboratory and clinic to tar...facell has licensed the U.S. commercial rights for onconase to Strativa Pharmaceuticals, a division of Par Pha...

Alfacell Receives NASDAQ Delisting Letter

...e development of a new class of targeted therapies for cancer and other life-threatening diseases. Alfacell has completed Phase III clinical trials of onconase in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related rolling New Drug Application, Alfacell is currently...

Alfacell Receives NASDAQ Non-Compliance Notification

...e development of a new class of targeted therapies for cancer and other life-threatening diseases. Alfacell has completed Phase III clinical trials of onconase in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related rolling New Drug Application, Alfacell is currently...

Alfacell Reports Financial Results for Third Quarter of Fiscal 2008

...ent expectations for the planned completion of the onconase rolling NDA. The company will be eligible to recei...nt in a confirmatory Phase IIIb clinical trial for onconase in patients suffering from unresectable malignant ...ses required to complete the final sections of the onconase rolling NDA. As the company has previously reporte...

Alfacell Announces Retirement of Chief Executive Officer

...us upon receiving marketing approval by the FDA of onconase for the treatment of malignant mesothelioma, a sig...lfacell in the event aggregate annual net sales of onconase exceed $100 million. "Tina's contributions to Alfacell and the science behind onconase have been immeasurable," said David Sidransky, M.D...

Alfacell Reports Financial Results for Second Quarter of Fiscal 2008

... in the confirmatory Phase IIIb clinical trial for onconase (ranpirnase) in patients suffering from unresectab...rmaceutical, Inc. for the commercialization of onconase in the U.S. by Strativa, the branded product d...th BL&H Co. Ltd., for the commercialization of onconase in Korea, Taiwan and Hong Kong. Under the agr...
Other Tags
(Date:5/30/2015)... (PRWEB) May 30, 2015 AVT, the ... quality assurance, is joining forces with leading proofing solutions ... to the worldwide printing market. , Under ... new software engine for its offline inspection solutions, which ... printing industry and its varying production workflow setups and ...
(Date:5/30/2015)... 30, 2015 The results of a ... has a high potential to cause mesothelioma, regardless of ... now on the Surviving Mesothelioma website. , ... Medicine in Lodz, Poland found that, among the 138 ... 1970 and 2012, all of them happened at plants ...
(Date:5/30/2015)... May 30, 2015 EHO offers a ... Portal that gives hospices the ability to manage their ... of this business model, EHO has been able to ... to its clients and survive among the giants of ... management systems three years ago, it has simplified the ...
(Date:5/30/2015)... 30, 2015 Cyclist Barry Haarde ... for the World 2015: Piles of Miles” near ... awareness about hemophilia and encourage individuals to support ... , Save One Life supports nearly 1,200 impoverished ... countries through direct sponsorships, scholarships and micro-enterprise grants. ...
(Date:5/30/2015)... 30, 2015 This year the ... Pulmonary Horizons to offer one of the most diverse ... discuss successful practices to diagnose, treat and manage patients ... Pulmonary Horizons Conference is Interaction with Multidisciplinary Healthcare ... Overall Needs of Patients with COPD," said Brian W. ...
Breaking Medicine News(10 mins):Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 2Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 3Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3
(Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
(Date:5/6/2015)... May 6, 2015 LifeBEAM, a developer of ... producer, announced today that they will expand their partnership ... first bio-sensing cycling helmet and the first joint project ... new colors in order to give cyclists more style ... addition, LifeBEAM and Lazer announced their plan to release ...
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
Other Contents